To study the role of BCL-XL in the tumor immune microenvironment, we chose several cell lines with which to produce syngeneic tumor models (MC38 for colon adenocarcinoma, 4T1 and Py8119 for breast cancer, and Renca for renal cancer). The gene discussed is BCL2L1; the disease is colon adenocarcinoma.